149 related articles for article (PubMed ID: 38194196)
1. Volumetric growth rate of incidentally found meningiomas on immunotherapy.
Berger A; Mullen R; Bernstein K; Mashiach E; Meng Y; Silverman JS; Sulman EP; Golfinos JG; Kondziolka D
J Neurooncol; 2024 Jan; 166(2):303-307. PubMed ID: 38194196
[TBL] [Abstract][Full Text] [Related]
2. Correlation of volumetric growth and histological grade in 50 meningiomas.
Soon WC; Fountain DM; Koczyk K; Abdulla M; Giri S; Allinson K; Matys T; Guilfoyle MR; Kirollos RW; Santarius T
Acta Neurochir (Wien); 2017 Nov; 159(11):2169-2177. PubMed ID: 28791500
[TBL] [Abstract][Full Text] [Related]
3. Volumetric growth rate of incidental asymptomatic meningiomas: a single-center prospective cohort study.
Delgado-López PD; Montalvo-Afonso A; Martín-Alonso J; Martín-Velasco V; Castilla-Díez JM; Galacho-Harriero AM; Ortega-Cubero S; Sánchez-Rodríguez A; Rodríguez-Salazar A
Acta Neurochir (Wien); 2021 Jun; 163(6):1665-1675. PubMed ID: 33751215
[TBL] [Abstract][Full Text] [Related]
4. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Brahmer JR; Lee JS; Ciuleanu TE; Bernabe Caro R; Nishio M; Urban L; Audigier-Valette C; Lupinacci L; Sangha R; Pluzanski A; Burgers J; Mahave M; Ahmed S; Schoenfeld AJ; Paz-Ares LG; Reck M; Borghaei H; O'Byrne KJ; Gupta RG; Bushong J; Li L; Blum SI; Eccles LJ; Ramalingam SS
J Clin Oncol; 2023 Feb; 41(6):1200-1212. PubMed ID: 36223558
[TBL] [Abstract][Full Text] [Related]
5. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M; Ohe Y; Ikeda S; Yokoyama T; Hayashi H; Fukuhara T; Sato Y; Tanaka H; Hotta K; Sugawara S; Daga H; Okamoto I; Kasahara K; Naito T; Li L; Gupta RG; Bushong J; Mizutani H
Int J Clin Oncol; 2023 Oct; 28(10):1354-1368. PubMed ID: 37548831
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
Han SJ; Reis G; Kohanbash G; Shrivastav S; Magill ST; Molinaro AM; McDermott MW; Theodosopoulos PV; Aghi MK; Berger MS; Butowski NA; Barani I; Phillips JJ; Perry A; Okada H
J Neurooncol; 2016 Dec; 130(3):543-552. PubMed ID: 27624915
[TBL] [Abstract][Full Text] [Related]
7. Growth rate of incidental meningiomas.
Firsching RP; Fischer A; Peters R; Thun F; Klug N
J Neurosurg; 1990 Oct; 73(4):545-7. PubMed ID: 2398385
[TBL] [Abstract][Full Text] [Related]
8. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients.
Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M
J Neurosurg; 2020 May; 134(5):1377-1385. PubMed ID: 32442973
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
[TBL] [Abstract][Full Text] [Related]
10. A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas.
Lee EJ; Kim JH; Park ES; Kim YH; Lee JK; Hong SH; Cho YH; Kim CJ
J Neurosurg; 2017 Nov; 127(5):971-980. PubMed ID: 28084908
[TBL] [Abstract][Full Text] [Related]
11. Treatment decision making based on the published natural history and growth rate of small meningiomas.
Sughrue ME; Rutkowski MJ; Aranda D; Barani IJ; McDermott MW; Parsa AT
J Neurosurg; 2010 Nov; 113(5):1036-42. PubMed ID: 20433281
[TBL] [Abstract][Full Text] [Related]
12. 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report.
Xiangsong Z; Xingchong S; Chang Y; Xiaoyan W; Zhifeng C
Clin Nucl Med; 2011 Nov; 36(11):1003-6. PubMed ID: 21975388
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET.
Combs SE; Welzel T; Habermehl D; Rieken S; Dittmar JO; Kessel K; Jäkel O; Haberkorn U; Debus J
Acta Oncol; 2013 Apr; 52(3):514-20. PubMed ID: 23402336
[TBL] [Abstract][Full Text] [Related]
14. Tumor Progression Following Petroclival Meningioma Subtotal Resection: A Volumetric Study.
Hunter JB; O'Connell BP; Carlson ML; Chambless LC; Yawn RJ; Wang R; Mistry A; Thompson RC; Weaver KD; Wanna GB
Oper Neurosurg (Hagerstown); 2018 Mar; 14(3):215-223. PubMed ID: 28541487
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
[TBL] [Abstract][Full Text] [Related]
16. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M; Ciuleanu TE; Lee JS; Schenker M; Zurawski B; Kim SW; Mahave M; Alexandru A; Peters S; Pluzanski A; Caro RB; Linardou H; Burgers JA; Nishio M; Martinez-Marti A; Azuma K; Axelrod R; Paz-Ares LG; Ramalingam SS; Borghaei H; O'Byrne KJ; Li L; Bushong J; Gupta RG; Grootendorst DJ; Eccles LJ; Brahmer JR
J Thorac Oncol; 2023 Aug; 18(8):1055-1069. PubMed ID: 37146754
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.
Nidamanuri P; Drappatz J
J Neurooncol; 2022 Apr; 157(2):271-276. PubMed ID: 35301639
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS; Tavernier SS; Yu H; Unger JM; Minichiello K; Highleyman L; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
JAMA Oncol; 2021 Sep; 7(9):1368-1377. PubMed ID: 34264316
[TBL] [Abstract][Full Text] [Related]
20.
Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
